Correction: Cost‑effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands
Saved in:
| Main Authors: | Sara W. Quist, Alexander V. van Schoonhoven, Stephan J. L. Bakker, Michał Pochopień, Maarten J. Postma, Jeanni M. T. van Loon, Jeroen H. J. Paulissen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Cardiovascular Diabetology |
| Online Access: | https://doi.org/10.1186/s12933-025-02752-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands
by: Sara W. Quist, et al.
Published: (2023-11-01) -
Cost-effectiveness of treatment with finerenone in mild to advanced stage chronic kidney disease patients with type 2 diabetes from a societal perspective
by: Maarten J Postma, et al.
Published: (2025-06-01) -
Cost effectiveness of empagliflozin in adult patients with chronic kidney disease in the Netherlands
by: Bart Slob, et al.
Published: (2024-01-01) -
Cost effectiveness of empagliflozin in adult patients with chronic kidney disease in the Netherlands.
by: Bart Slob, et al.
Published: (2024-01-01) -
Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes
by: Gerasimos Filippatos, et al.
Published: (2025-02-01)